KR101819874B1 - 암 세포를 선택적으로 죽이는 trail 강화제 - Google Patents

암 세포를 선택적으로 죽이는 trail 강화제 Download PDF

Info

Publication number
KR101819874B1
KR101819874B1 KR1020177014484A KR20177014484A KR101819874B1 KR 101819874 B1 KR101819874 B1 KR 101819874B1 KR 1020177014484 A KR1020177014484 A KR 1020177014484A KR 20177014484 A KR20177014484 A KR 20177014484A KR 101819874 B1 KR101819874 B1 KR 101819874B1
Authority
KR
South Korea
Prior art keywords
trail
cells
compound
apoptosis
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177014484A
Other languages
English (en)
Korean (ko)
Other versions
KR20170063980A (ko
Inventor
블라디미르 크라브첸코
리차드 제이. 울레비치
킴 디. 잔다
Original Assignee
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 스크립스 리서치 인스티튜트 filed Critical 더 스크립스 리서치 인스티튜트
Publication of KR20170063980A publication Critical patent/KR20170063980A/ko
Application granted granted Critical
Publication of KR101819874B1 publication Critical patent/KR101819874B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177014484A 2013-03-19 2014-03-19 암 세포를 선택적으로 죽이는 trail 강화제 Expired - Fee Related KR101819874B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361803177P 2013-03-19 2013-03-19
US61/803,177 2013-03-19
PCT/US2014/031235 WO2014153415A2 (en) 2013-03-19 2014-03-19 Trail enhancers for the selective killing of cancer cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157030159A Division KR101743383B1 (ko) 2013-03-19 2014-03-19 암 세포를 선택적으로 죽이는 trail 강화제

Publications (2)

Publication Number Publication Date
KR20170063980A KR20170063980A (ko) 2017-06-08
KR101819874B1 true KR101819874B1 (ko) 2018-01-17

Family

ID=51581796

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177014484A Expired - Fee Related KR101819874B1 (ko) 2013-03-19 2014-03-19 암 세포를 선택적으로 죽이는 trail 강화제
KR1020157030159A Expired - Fee Related KR101743383B1 (ko) 2013-03-19 2014-03-19 암 세포를 선택적으로 죽이는 trail 강화제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157030159A Expired - Fee Related KR101743383B1 (ko) 2013-03-19 2014-03-19 암 세포를 선택적으로 죽이는 trail 강화제

Country Status (8)

Country Link
US (2) US9604950B2 (https=)
EP (1) EP2976076B1 (https=)
JP (1) JP6307149B2 (https=)
KR (2) KR101819874B1 (https=)
CN (1) CN105228618A (https=)
AU (1) AU2014236003A1 (https=)
CA (1) CA2907668C (https=)
WO (1) WO2014153415A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2976076B1 (en) 2013-03-19 2020-03-04 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells
US10195177B2 (en) 2015-10-01 2019-02-05 The University Of Toledo Use of acyl-homoserine lactone derivatives as anti-thrombotic agents
CN105504000B (zh) * 2016-01-21 2019-06-07 福建农林大学 一种筛选n-酰基高丝氨酸内酯类模拟物的方法
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12533346B2 (en) 2016-04-19 2026-01-27 Axcess Global Sciences, Llc Administration of berberine metabolites
US12599579B2 (en) 2016-04-19 2026-04-14 Axcess Global Sciences, Llc Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
US11026929B2 (en) 2016-04-19 2021-06-08 Keto Patent Group, Inc. Administration of berberine metabolites
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12521378B2 (en) 2016-04-19 2026-01-13 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate salt blend and related compounds in humans
US20230346721A1 (en) 2018-04-18 2023-11-02 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for delivery of ketone bodies
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
EP3666908A1 (en) * 2016-06-03 2020-06-17 Institut national de recherche pour l'agriculture, l'alimentation et l'environnement Diet controlled expression of a nucleic acid encoding a pro-apoptotic protein
US12171735B2 (en) 2017-04-19 2024-12-24 Axcess Global Sciences, Llc Administration of butyrate, beta-hydroxybutyrate, cannabidiol, and related compounds in humans
CN110935012A (zh) * 2019-12-19 2020-03-31 东北师范大学 一种用于治疗肿瘤的药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010477A1 (en) 2005-04-07 2007-01-11 Dolnick Bruce J Acyl homoserine lactones for inhibition of cell growth

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924195D0 (en) * 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0122914D0 (en) * 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
JP2004231556A (ja) * 2003-01-29 2004-08-19 Nobuhiko Nomura アポトーシス誘導剤
WO2004075839A2 (en) * 2003-02-21 2004-09-10 Irm Llc Methods and compositions for modulating apoptosis
WO2007007207A2 (en) * 2005-04-13 2007-01-18 Khairia Youssef Pharmaceutical compositions of 3, 5 -bis (arylidene) -4 -piperidones and analogues there of for modulating cell proliferation
GB0610042D0 (en) * 2006-05-22 2006-06-28 Univ Nottingham Substituted n-acyl homoserine lactones
EP2448930B1 (en) * 2009-07-03 2017-02-15 The National Institute for Biotechnology in the Negev Ltd. N-((S)-2-Oxo-tetrahydro-furan-3-yl)-amide derivatives as inhibitors of the bacterial quorum sensing for treating plant or animal diseases and for preventing the formation of biofilms on medical devices
EP2976076B1 (en) 2013-03-19 2020-03-04 The Scripps Research Institute Trail enhancers for the selective killing of cancer cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070010477A1 (en) 2005-04-07 2007-01-11 Dolnick Bruce J Acyl homoserine lactones for inhibition of cell growth

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters, 21(9), 2702-2705, 2011.
Chemical Communications, 47, 7378-7380, 2009.

Also Published As

Publication number Publication date
US9765061B2 (en) 2017-09-19
KR101743383B1 (ko) 2017-06-02
US20160272603A1 (en) 2016-09-22
CN105228618A (zh) 2016-01-06
US20170101400A1 (en) 2017-04-13
US9604950B2 (en) 2017-03-28
EP2976076A4 (en) 2016-11-16
EP2976076B1 (en) 2020-03-04
CA2907668C (en) 2021-02-23
JP2016515546A (ja) 2016-05-30
CA2907668A1 (en) 2014-09-25
WO2014153415A3 (en) 2015-01-08
JP6307149B2 (ja) 2018-04-04
WO2014153415A2 (en) 2014-09-25
KR20150135387A (ko) 2015-12-02
KR20170063980A (ko) 2017-06-08
AU2014236003A1 (en) 2015-11-05
EP2976076A2 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
KR101819874B1 (ko) 암 세포를 선택적으로 죽이는 trail 강화제
Achanta et al. A boronic-chalcone derivative exhibits potent anticancer activity through inhibition of the proteasome
Buss et al. Beneficial effects of Mammalian target of rapamycin inhibition on left ventricular remodeling after myocardial infarction
US20220354857A1 (en) Aldehyde conjugates and uses thereof
AU2013275197B2 (en) Heteroarylcarboxylic acid ester derivative
TWI830875B (zh) 化合物在製備用於抑制激酶之組合物的用途
CN105682655A (zh) 抗微生物化合物
WO2012140504A1 (en) Therapeutic compounds
CN106562951B (zh) 一种呋喃类d-3-磷酸甘油酸脱氢酶别构抑制剂及其应用
US20200010507A1 (en) Inhibition of the aggregation of transthyretin by specific binding of peptides to aggregation-driving segments
US20240269106A1 (en) Small molecule modulator targeting a rare histone modification regulating adipogenesis and pharmaceutical formulation thereof
US9458123B2 (en) Methods, pharmaceutical compositions, therapeutic systems, and compounds for treating B cell malignancies
US20240270692A1 (en) S(+) form of 4-(2,4-difluorophenyl)-2-(1h-indol-3-yl)-4-oxo-butanoic acid
TWI504390B (zh) 苯醌類化合物應用於抑制黑色素瘤細胞之Ｗｎｔ／β－ｃａｔｅｎｉｎ訊息途徑之用途
JP2008519856A (ja) 強力なリポ多糖金属イオン封鎖剤としての疎水性ポリアミンアミド類
Wang et al. Betulinic acid reduces inflammation in rats with sepsis‐induced myocardial dysfunction by inhibiting TLR4/MyD88/NF‐κB signaling pathway
RU2440998C1 (ru) Производные 4-арилкумаринов и противоопухолевое лекарственное средство на их основе
WO2025079163A1 (ja) ４－（２，４－ジフルオロフェニル）－２－（１ｈ－インドール－３－イル）－４－オキソ－ブタン酸のｓ（＋）体
Misra et al. N-(2-Bromo-4-fluorophenyl)-3-(3, 4-dihydroxyphenyl)-acrylamide (CPAM), a small catecholic amide as an antioxidant, anti diabetic and antibacterial compound
US10519179B2 (en) Highly efficient NRF2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
KR20230009454A (ko) 암 줄기 세포 표적화 및 전이 예방을 위한 9-아미노-독시사이클린의 미리스토일 유도체
Lim Discovery and characterisation of novel anticancer compounds acting on sphingosine kinase
Isaacs The effect of melatonin treatment on doxorubicin-induced skeletal muscle atrophy within a cancer model
HK1234725A1 (en) Opsin-binding ligands, compositions and methods of use
NZ703195B2 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20240112

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240112

St.27 status event code: N-4-6-H10-H13-oth-PC1903